Dataset from Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone

- Participants suffering from active rheumatoid arthritis who had an inadequate response
to methotrexate were evaluated for improvement of disease activity (efficacy) when
taking GLPG0634 as monotherapy (3 different doses - 50 milligram (mg), 100 mg and 200 mg
once daily) or matching placebo for 24 weeks.

- During the course of the study, patients were also examined for any side effects that
could occur (safety and tolerability), and the amount of GLPG0634 present in the blood
(Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of
action-related parameters in the blood (Pharmacodynamics) were determined. Also, the
effects of different doses of GLPG0634 administration on participants' disability,
fatigue and quality of life were evaluated.